The latest update is out from Astria Therapeutics (ATXS).
Astria Therapeutics, Inc. expanded its Board of Directors from eight to nine members and appointed Sunil Agarwal, M.D. as a new director, starting April 8, 2024. Dr. Agarwal, who will also serve on the Science and Technology Committee, will be a Class III director until the next annual stockholders’ meeting. He will receive a stock option to purchase 28,200 shares at $11.40 each, vesting over three years, and an indemnification agreement similar to those of other directors.
See more data about ATXS stock on TipRanks’ Stock Analysis page.
